Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6749410 | 0.90 | HDAC6 (0.37) | HDAC6ICAM1USP14HDAC3HDAC1 | |
| SCHEMBL6747160 | 0.73 | NOX1 (0.37) | HDAC6ICAM1NOX1LMNAPKM | |
| SCHEMBL6749505 | 0.72 | HDAC6 (0.42) | HDAC6ICAM1HDAC3HDAC1LMNA | |
| SCHEMBL9832621 | 0.71 | NOX1 (0.61) | HDAC6NOX1 | |
| SCHEMBL6745545 | 0.71 | ICAM1 (0.66) | ICAM1 | |
| Hydrochloric Acid SCHEMBL6747679 | 0.71 | HDAC6 (0.32) | HDAC6 | |
| SCHEMBL6747437 | 0.70 | ICAM1 (0.55) | ICAM1 | |
| SCHEMBL9830999 | 0.68 | SNCA (0.54) | NOX1LMNAPKMNPSR1 | |
| SCHEMBL6745730 | 0.66 | HDAC6 (0.43) | HDAC6ICAM1 | |
| SCHEMBL6747647 | 0.66 | HDAC6 (0.39) | HDAC6ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | HDAC6 1953/4885ICAM1 412/4885USP14 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.